InSphero in TOP 10 for Third Time in as Many Years

Share Article

For the third year running, InSphero has been named as one of the top ten start-ups in Switzerland, finishing fifth in the 2013 Top 100 Swiss Start-Up Rankings. The latest rankings thus confirm the company’s position as a leading supplier of three-dimensional microtissues for in vitro drug testing.

InSphero, a spin-off of ETH Zurich and the University of Zurich, came fifth in the 2013 Top 100 Swiss Start-Up Rankings, featuring in the Top 10 for the third year running after ranking second in 2012 and sixth in 2011. This year’s rankings, which are compiled by a panel of 100 experts from the Swiss start-up scene, were published in Switzerland on 19 September 2013. Every year, each expert puts forward a shortlist of the ten most promising start-ups, awarding ten points to the top choice and one point to the company in tenth. The start-ups with the highest scores overall enter the Top 100 rankings.

While InSphero has dropped three places compared to last year, its strong ranking in fifth place is a clear indication of the company’s continued success as a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. “We’re delighted to be in the Top 10 once again,” explains Dr Jan Lichtenberg, InSphero’s Chief Executive Officer and co-founder. “This recognition is surely down to our growing customer and product base. By taking the difficult road and immediately targeting the major pharmaceutical companies when the start-up was founded four years ago, meanwhile we have managed to carve out a name for ourselves within our market segment and for many InSphero has become synonymous with 3D microtissue. What’s more, there is still plenty of market potential as the majority of the pharmaceutical and cosmetics industry still works with 2D technology and 3D is yet to make its mark in the field.” InSphero has now embarked on an expansion course. In the last few months, for instance, the company has stepped up its production with a view to expanding its product portfolio to include different models of 3D microtissue, recruited new members of staff and opened additional branches in the USA and in Germany. “We look forward to continuing this growth in years to come,” says Dr Lichtenberg.

To find out more about InSphero visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Manuela Vujevic
Follow us on
Visit website